Breast Neoplasms, Triple Negative Breast Neoplasms
Conditions
Brief summary
Primary Objective: To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative breast cancers (TNBC). Secondary Objectives: 1. To examine the safety and tolerability of dasatinib in patients with operable TNBC 2. To explore potential intracellular mechanisms which impact dasatinib effect on cellular localization of EGFR in operable TNBC. 3. To examine the pathologic complete response (pCR) rates to standard neoadjuvant chemotherapy in nEGFR+ TNBC 4. To examine breast cancer recurrence rates and patterns of metastatic recurrent in nEGFR+ TNBC
Interventions
DRUGDasatinib
100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
PROCEDUREConventional Surgery
Undergo surgery
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
University of Wisconsin, Madison
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for nEGFR testing: * Patients must have histologically or cytologically confirmed Stage I-III triple negative breast cancer * estrogen receptor (ER) and progesterone receptor (PR) must be \<1% by standard assay methods * human epidermal growth factor receptor-2 (HER2) must be either 0, 1+ by immunohistochemistry (if 2+, in situ hybridization method used to define HER2) OR have HER2: 17 centromere signal of \<2.0 using a standard in situ hybridization method * No prior therapy for current breast cancer * Meet criteria for neoadjuvant chemotherapy or primary breast surgery, as determined by primary oncologist and surgeon Inclusion Criteria for study therapy: * nEGFR positive * Eastern Cooperative Oncology Group (ECOG) performance status ≤1 * Patients must have normal organ and marrow function as defined below: * leukocytes ≥3,000/mcL * absolute neutrophil count ≥1,500/mcL * platelets ≥150,000/mcL * total bilirubin \<1.25x institutional upper limit of normal * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal * creatinine within normal institutional limits OR creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 30 days after the final dose. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who are receiving any other investigational agents * Patients not able to swallow oral medications or with gastrointestinal conditions that may impact absorption of dasatinib. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib. * Patients receiving any medications or substances that are moderate or strong inhibitors or inducers of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, medications should be reviewed by the UW Pharmacy Research Center for any contraindicated medications. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. * H2 antagonists and proton pump inhibitors are not allowed * Anticoagulants (ie. Coumadin, heparin, anti-Xa inhibitors) and anti-platelet agents (ie. aspirin) are not allowed. NSAIDS and acetaminophen are allowed on study. * Medications known to prolong QTC are not allowed (See Appendix B) * No history of prolonged QTC or cardiomyopathy unless normal QTC and ejection fraction confirmed within 1 month prior to study entry. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because dasatinib is a pregnancy category D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with dasatinib, breastfeeding should be discontinued if the mother is treated with dasatinib and not resumed until at least 2 weeks after the final dose. * HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with dasatinib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated. * Contraindication to repeat breast biopsy (neoadjuvant chemotherapy group)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Membrane Epidermal Growth Factor Receptor (EGFR) Expression, Measured by VECTRA Imaging | 7-10 days | An increase of at least 25% from baseline to post-dasatinib treatment will be considered significant. VECTRA is an automated pathology imaging system used to detect biomarkers in samples. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Up to 4 weeks | Safety and tolerability of dasatinib in participants with operable Triple negative breast cancer (TNBC) will be based on NCI Adverse Events (AE) Version 4.0 and will be assessed by frequency tables. AEs were collected on day 1 of treatment and a minimum of 14 days after the last dose. AEs reported here were ranked as either possibly related, probably related, or definitely related to the study intervention. All AEs (including not related and unlikely related) are summarized in the AE section. |
| Number of Participants With Pathologic Complete Response (pCR) | Up to 4 weeks | Examine pCR rates to standard neoadjuvant chemotherapy in nuclear Epidermal Growth Factor Receptor (nEGFR) + TNBC. pCR will be defined as ypT0 ypNO (absence of cancer in breast tissue and lymph nodes) an assessed by the investigator. |
| Number of Participants With No Evidence of Disease (NED) at Long-term Follow up | up to 24 months | — |
Countries
United States
Participant flow
Recruitment details
Eligible patients were entered on study at the University of Wisconsin Carbone Cancer Center. Participants were enrolled from May 2017 to June 2020.
Participants by arm
| Arm | Count |
|---|---|
| Dasatinib 100mg Dasatinib 100mg for 7-10 days until day prior to surgery
Dasatinib: 100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
Conventional Surgery: Undergo surgery
Laboratory Biomarker Analysis: Correlative studies | 5 |
| Total | 5 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 1 |
Baseline characteristics
| Characteristic | Dasatinib 100mg |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants |
| Age, Customized 30-39 years | 2 Participants |
| Age, Customized 40-49 years | 1 Participants |
| Age, Customized 50-59 years | 1 Participants |
| Age, Customized 60-69 years | 0 Participants |
| Age, Customized 70-79 years | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 5 Participants |
| Region of Enrollment United States | 5 participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 5 |
| other Total, other adverse events | 5 / 5 |
| serious Total, serious adverse events | 1 / 5 |
Outcome results
Primary
Plasma Membrane Epidermal Growth Factor Receptor (EGFR) Expression, Measured by VECTRA Imaging
An increase of at least 25% from baseline to post-dasatinib treatment will be considered significant. VECTRA is an automated pathology imaging system used to detect biomarkers in samples.
Time frame: 7-10 days
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Dasatinib 100mg | Plasma Membrane Epidermal Growth Factor Receptor (EGFR) Expression, Measured by VECTRA Imaging | Baseline | 0.54 percentage plasma EGFR |
| Dasatinib 100mg | Plasma Membrane Epidermal Growth Factor Receptor (EGFR) Expression, Measured by VECTRA Imaging | After Treatment | 0.40 percentage plasma EGFR |
Secondary
Number of Participants With No Evidence of Disease (NED) at Long-term Follow up
Time frame: up to 24 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dasatinib 100mg | Number of Participants With No Evidence of Disease (NED) at Long-term Follow up | NED at 16 months (subsequently lost to follow up) | 1 Participants |
| Dasatinib 100mg | Number of Participants With No Evidence of Disease (NED) at Long-term Follow up | NED at 24 months | 4 Participants |
Secondary
Number of Participants With Pathologic Complete Response (pCR)
Examine pCR rates to standard neoadjuvant chemotherapy in nuclear Epidermal Growth Factor Receptor (nEGFR) + TNBC. pCR will be defined as ypT0 ypNO (absence of cancer in breast tissue and lymph nodes) an assessed by the investigator.
Time frame: Up to 4 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dasatinib 100mg | Number of Participants With Pathologic Complete Response (pCR) | 1 Participants |
Secondary
Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks
Safety and tolerability of dasatinib in participants with operable Triple negative breast cancer (TNBC) will be based on NCI Adverse Events (AE) Version 4.0 and will be assessed by frequency tables. AEs were collected on day 1 of treatment and a minimum of 14 days after the last dose. AEs reported here were ranked as either possibly related, probably related, or definitely related to the study intervention. All AEs (including not related and unlikely related) are summarized in the AE section.
Time frame: Up to 4 weeks
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Fatigue | 4 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Creatinine Increase | 1 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Low E-GFR | 1 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Nausea | 1 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Insomnia | 1 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Body Aches | 1 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Constipation | 1 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Headache | 1 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Dyspepsia | 1 adverse events |
| Dasatinib 100mg | Number of Treatment-emergent Adverse Events [Safety and Tolerability] up to 4 Weeks | Anemia | 2 adverse events |